« Back
Home /
Eltrombopag (Olamine)

Eltrombopag (Olamine)

Item no.	HY-15306A-50mg
Manufacturer	MedChem Express
CASRN	496775-62-3
Amount	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Neuroinflammation Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.96
Formula	C29H36N6O6
Citations	Eur J Clin Pharmacol. 2022 Aug 3.<br/>Front Pharmacol. 2020 Nov 16;11:582625.<br/>Alzheimers Res Ther. 2024 Jun 3;16(1):121.<br/>Blood Adv. 2017 Feb 28;1(7):468-476.<br/>BMC Cancer. 2020 Nov 30;20(1):1171.<br/>Cells. 2022, 11(3), 319.<br/>Curr Microbiol. 2021 Feb 21.<br/>J Pharm Biomed Anal. 235, 25 October 2023, 115683<br/>J Thromb Haemost. 2022 May 27.<br/>Virology. 2023 Jun 21.<br/>Viruses. 2019 Apr 25;11(4):385. <br/>[1]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.<br/>[2]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.<br/>[3]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel). 2021 Nov 9;10(11):1372.<br/>[4]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.<br/>[5]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47(5):1696-702.
Smiles	O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O.NCCO.NCCO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Eltrombopag diethanolamine salt; SB-497115GR
Available
Product Description	Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	564.63
Clinical Information	Launched
Manufacturers Research Area	Cancer; Infection; Cardiovascular Disease
Solubility	DMSO : ≥ 50 mg/mL
Target	Apoptosis; Bacterial; Thrombopoietin Receptor
Manufacturers Target	Apoptosis; Bacterial; Thrombopoietin Receptor
Manufacturers Pathway	Anti-infection; Apoptosis; Immunology/Inflammation
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15306A-50mg-safety-datasheet.pdf